← Eichor
Condition: Tnbc Triple Negative Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Tnbc Triple Negative Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TNBC Gut Microbiota During Neoadjuvant Treatment
NA · 1 location(s) · Scripps Health · NCT06610097Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Phase 2 · 4 location(s) · Providence Health & Services · NCT06353997OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infi
Phase N/A · 28 location(s) · The Netherlands Cancer Institute · NCT06476119Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Phase 3 · 6 location(s) · Natureceuticals Sdn Bhd · NCT07669467Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
Phase 3 · 2 location(s) · UNICANCER · NCT06606730A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04683679Saci Nivo Rela for TNBC
Phase 1/Phase 2 · 1 location(s) · Yale University · NCT06963905Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · 356 location(s) · Gilead Sciences · NCT05633654A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 · 1 location(s) · Monopar Therapeutics · NCT06337084Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast
Phase 2 · 1 location(s) · West China Hospital · NCT05447702Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06313463Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
Phase 2 · 1 location(s) · Wake Forest University Health Sciences · NCT04677816Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative
Phase 3 · 1 location(s) · Akeso · NCT06767527Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Phase N/A · 1 location(s) · Fudan University · NCT07705438A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Phase 2 · 7 location(s) · Dana-Farber Cancer Institute · NCT04434040Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Phase 2 · 2 location(s) · Baylor Breast Care Center · NCT05020860Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Maligna
Phase N/A · 14 location(s) · Tempus AI · NCT07211178A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations o
NA · 6 location(s) · Institut Curie · NCT03017573Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemother
Phase 1 · 6 location(s) · National Cancer Institute (NCI) · NCT05422794The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast
Phase 2 · 1 location(s) · Huihua Xiong · NCT06125080Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Phase N/A · 8 location(s) · Elephas · NCT07327489A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1 · 6 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06908928Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06355037Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Tri
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07401537
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.